Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.

被引：0
|
作者：
Udagawa, Shohei [1 ]
Osumi, Hiroki [1 ]
Ooki, Akira [1 ]
Wakatsuki, Takeru [1 ]
Fukuoka, Shota [1 ]
Yoshino, Koichiro [1 ]
Tamba, Mikako [1 ]
Ogura, Mariko [1 ]
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
Shinozaki, Eiji [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-237-255; 261-492-3532-2370-7650-2700; 261-566-148; 261-492-9019; 298-145-222-184-4809-5347; 3282-415; 7; 6; 4; 3; 2; 38092-18849; 38092-22188; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：142 / 142
页数：1
相关论文
共 50 条
  • [31] Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study.
    Stintzing, Sebastian
    von der Heyde, Eyck
    Wierecky, Jan
    Burkle, Dieter
    Forstbauer, Helmut
    Huebner, Gerdt
    Schmidt, Burkhard
    Schroeder, Jan
    Distelrath, Andrea
    Flum, Marion
    Reichenbach, Frank
    Arnold, Dirk
    Fritsch, Ralph M.
    Gerger, Armin
    Hegewisch-Becker, Susanna
    Vogel, Arndt
    Wagner, Anna Dorothea
    Winder, Thomas
    Koeberle, Dieter
    Prager, Gerald W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 34 - 34
  • [32] Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus
    Shi, Liangliang
    Zou, Zhenwei
    Ding, Qian
    Liu, Qing
    Zhou, Hongxia
    Hong, Xiaohua
    Peng, Gang
    CANCER BIOLOGY & THERAPY, 2019, 20 (04) : 431 - 434
  • [33] Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
    Ros, Javier
    Rodriguez-Castells, Marta
    Saoudi, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Tabernero, Josep
    Elez, Elena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 797 - 806
  • [34] Clinicopathologic Features of BRAF V600E-Mutant Anaplastic Thyroid Carcinoma
    Chen, Tiffany
    Wong, Kristine
    Barletta, Justine
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 571 - 572
  • [35] Clinicopathologic features and impact of metastasectomy in patients with BRAF-mutant metastatic colorectal cancer.
    Zhang, Jianwei
    Shen, Cailu
    Li, Jianxia
    Wu, Zehua
    Hu, Huabin
    Cai, Yue
    Xie, Xiaoyu
    Ling, Jiayu
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
    Yaeger, Rona
    Kotani, Daisuke
    Mondaca, Sebastian
    Parikh, Aparna R.
    Bando, Hideaki
    Van Seventer, Emily E.
    Taniguchi, Hiroya
    Zhao, HuiYong
    Thant, Claire N.
    de Stanchina, Elisa
    Rosen, Neal
    Corcoran, Ryan B.
    Yoshino, Takayuki
    Yao, Zhan
    Ebi, Hiromichi
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7089 - 7097
  • [37] Clinicopathologic Features of BRAF V600E-Mutant Anaplastic Thyroid Carcinoma
    Chen, Tiffany
    Wong, Kristine
    Barletta, Justine
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 571 - 572
  • [38] Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma
    Tina Dasgupta
    Aleksandra K. Olow
    Xiaodong Yang
    Rintaro Hashizume
    Theodore P. Nicolaides
    Maxwell Tom
    Yasuyuki Aoki
    Mitchel S. Berger
    William A. Weiss
    Lukas J. A. Stalpers
    Michael Prados
    C. David James
    Sabine Mueller
    Daphne A. Haas-Kogan
    Journal of Neuro-Oncology, 2016, 126 : 385 - 393
  • [39] Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter
    Huillard, Olivier
    Tenenbaum, Florence
    Clerc, Jerome
    Goldwasser, Francois
    Groussin, Lionel
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5639 - 5639
  • [40] Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study
    Koeberle, D.
    Kisro, J.
    Muller-Huesmann, H.
    Wierecky, J.
    von der Heyde, E.
    Stuebs, P.
    Buerkle, D.
    Schmidt, B.
    Forstbauer, H.
    Nora, H.
    Reichenbach, F.
    Arnold, D.
    Fritsch, R.
    Gerger, A.
    Hegewisch-Becker, S.
    Vogel, A.
    Winder, T.
    Prager, G.
    Stintzing, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 158 - 158
12345